Regorafenib for recurrent high-grade glioma: a unicentric retrospective analysis of feasibility, efficacy, and toxicity

We describe here 11 consecutive patients with recurrence of high-grade glioma treated with regorafenib at our university medical center. The majority of patients had MGMT promoter methylation (9/11 cases). Regorafenib was given as 2nd line systemic treatment in 6/11 patients and 3rd or higher line t...

Descripción completa

Detalles Bibliográficos
Autores principales: Treiber, Hannes, von der Brelie, Christian, Malinova, Vesna, Mielke, Dorothee, Rohde, Veit, Chapuy, Claudia Ilse
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492606/
https://www.ncbi.nlm.nih.gov/pubmed/35725846
http://dx.doi.org/10.1007/s10143-022-01826-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492606/
https://www.ncbi.nlm.nih.gov/pubmed/35725846
http://dx.doi.org/10.1007/s10143-022-01826-z

Ejemplares similares